Abstract
Background The UK Government intends to implement a ‘smokefree generation’ policy prohibiting the sale of all tobacco products to people born after 2008. National surveys provide comprehensive data on cigarette smoking, but little is known about patterns of non-cigarette tobacco smoking across key population groups.
Methods Using data from a nationally-representative cross-sectional survey of adults (≥18y) in England, collected monthly between September-2013 and September-2023 (n=196,721), we estimated time trends in non-cigarette tobacco smoking prevalence, overall and by age, gender, occupational social grade, region, ethnicity, and vaping status. Interviews were conducted face-to-face until March-2020 and via telephone thereafter.
Results From September-2013 to September-2023, there was a non-linear increase in non-cigarette tobacco smoking prevalence (from 0.36% to 1.68%; PR=4.72 [95%CI=3.43-6.48]). Prevalence was relatively stable up to February-2020 (at an average of 0.46%), then increased sharply at the start of the Covid-19 pandemic, to 0.90% [0.82-0.99%] in March-2020. This was followed by a steadier rise, peaking at 1.97% in May-2022, before falling slightly to 1.68% by September-2023. As a result, in 2022/23, one in ten smokers (10.8% [9.64-12.0%]) used non-cigarette tobacco. This rise was observed across all subgroups but was most pronounced among younger adults (e.g., reaching 3.21% of 18-year-olds vs. 1.09% of 65-year-olds). Prevalence was consistently higher among men (2.17% in September-2023 vs. 1.07% women) and current vapers (4.71% vs. 1.25% non-vapers).
Conclusions While exclusive use of non-cigarette combustible tobacco remains rare among adults in England, it increased at the start of the Covid-19 pandemic (at the same time as survey methods changed) but subsequently continued increasing steadily until May-2022. As of September-2023, there were ∼772,800 adult non-cigarette tobacco smokers in England; around five times more than a decade earlier. The rise in prevalence differed by age, with a more pronounced rise leading to higher prevalence among younger than older ages.
What is already known on this topic There is good evidence from nationally-representative population surveys on the prevalence and patterns of cigarette smoking in England. Less is known about use of other combustible tobacco products.
What this study adds Prevalence of non-cigarette tobacco smoking has risen substantially since the start of the Covid-19 pandemic, particularly among younger adults. As a result, one in 10 smokers in England now does not smoke cigarettes at all but smokes some other form of combustible tobacco.
How this study might affect research, practice or policy The UK Government is planning to ban the sale of tobacco products to those born after 2008. The inclusion of non-cigarette combustible tobacco products under this policy is likely to be important for achieving the greatest reduction in youth uptake of tobacco smoking, as it would ensure young people who are unable to legally buy cigarettes do not buy other combustible tobacco products that are similarly harmful to health.
Competing Interest Statement
JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Clinical Protocols
Funding Statement
Cancer Research UK (PRCRPG-Nov21\100002) funded the Smoking Toolkit Study data collection and SJ's salary. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymized when received by UCL.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available from the corresponding author on reasonable request.
